Abstract

BackgroundThe patient global assessment of disease activity is a crucial component of validated disease activity scores, response criteria, and the ACR/EULAR definition of remission in rheumatoid arthritis (RA). Recent work...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The Patient Global Assessment of Disease Activity in Rheumatoid Arthritis: Identification of Underlying Latent Factors.
John M Davis ... Divya N V Challa
Rheumatology and therapy | VOL. 4
John M Davis, et. al.John M Davis ... Divya N V Challa
09 May 2017
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.
Susan H Ballinger ... Ildy M Katona
Arthritis and rheumatism | VOL. 40
Susan H Ballinger, et. al.Susan H Ballinger ... Ildy M Katona
01 Nov 1997
THU0596 Physician's Global Assessment of Disease Activity in Rheumatoid Arthritis, Reflects Solely Objective Measures and Disregards Patient Reported Outcomes
G Eugenio ... C Duarte
Annals of the Rheumatic Diseases | VOL. 75
G Eugenio, et. al.G Eugenio ... C Duarte
01 Jun 2016
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis
Carlomaurizio Montecucco ... Garifallia Sakellariou
Annals of the Rheumatic Diseases | VOL. 81
Carlomaurizio Montecucco, et. al.Carlomaurizio Montecucco ... Garifallia Sakellariou
27 May 2022
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers